2Plutzky J. Inflammatory pathways in arteriosclerosis and acute coronary syndromes[J].Am J cordial,2001, 88:10.
3Biasucci L M, Liuzzo G, Grille R L, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability[J].Circulation,1999, 99:855.
4Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease;FRISC Study Group[J].N Engl J Med,2000, 343:1139.
5Marschner I C, Colquhoun D, Simes R J, et al. long-term risk stratification for survivors of acute coronary syndromes. LIPID Study Investigators[J].J Am Call Cardiol,2001, 38:56.
6Albert M A, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactance protein levels[J].JAMA,2001,286:64.
7Ridker P M, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events[J].N Engl J Med,2001, 344:1959.
8Libby P, Ridker P M, Maseri A. Inflammation and Arteriosclerosis[J].Circulation,2002,105:1135.
9Pasterkamp G, Schoneveld A H, Vander Wal A C, et al. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptwred plaques of femoral and coonary arteries[J].Arterioscler Thromb Vasc Biol,1999,19:54.
10Ridker P M, Rifai N, Rose L, et al. Comparison of C-Reactive protein and low-density lipoprotein Cholesterol levels in the prediction of First cardiovascular events[J].N Engl J Med,2002, 347:1557.
二级参考文献16
1Kai H,Jkeda H,Yasukwa H,et al.Peripheral blood levels of matrix metalloproteinases-2 and-9 are elevated in patients with acute coronary syndromes[J].J Am Coll Cardiol,1998,32:368-372
2Ueda H,Imazu M,Hayashi Y,et al.Immunohistochemical analysis of hepatocyte growth factor in human coronary atherectomy specimens:comparison with transforming growth factor beta isoforms[J].Virchows Arch,1997,430:407-415
3Sato T,Yoshinouchi T,sugimoto T,et al.Prognostic value of serum hepatocyte growth factor in patients with acute coronary syndromes[J].Jpn Circ J,1999,63:583-588
4Xu Q,Kiechl S,Mayr M,et al.Association of serum antibodies to heatshock protein 65 with carotid atherosclerosis:clinical significance determined in a follow-un study[see comments][J].Circulation,1999,100:1169-1174
5Gawaz M,Reininger A,Neumann FJ,Platelet function and pletelet-leukocyte adhesion in symptomatic coronary disease.Effects of intravenous magnesium[J].Throm Res,1996,83:341-349
6Carvili DGM,Dimitrijeric N,Walsh M,et al.Thrombus precursor protein:marker of thrombosis early in the pathogenesis of myocardial infarction[J].Clin Chem,1996,42:1537-1541
7Lee L,Ewald GA,Mckenzie CR,et al.The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction[J].Arterioscler Thromb Vasc Biol,1997,17:628-633
8Zhang YX,Cliff WJ,WSchoefl GI,et al.Coronary C-reactive protein distribution:is relation to deverlopment of atheroslerosis[J].Atherosclerosis,1999,145:375-379
9Lagrand WK,Visser CA,Hermens WT,et al.C-reactive protein as a cardiovascular risk factor:more than an epiphenomenon?[J].Circulation,1999,100:96-102
10Maresca G,Di Blasio A,Marchioli R,et al.Measuring plasma fibrinogen to predict stroke and myocardial infarction:an update[J].Arterioscler Thromb Vasc Biol,1999,19:1368-1377
5[1]Waters DD,Azar RR.Should intensive cholesterol lowering play a role in management of acult coronary ayndromes[J].Am J Cardiol,2000,86 suppl:35J-43J.
6[4]Cannon CP,Braunwald E,McCabe CH,et al.Pravastatin or atorvastatin evalution and infection therapy-thrombolysis in myocardial infarction 22 investigators,Intensive versus moderate lipid lowering with statin after acute coronary syndromes[J].N Engl J Med,2004,350(15):1495-1504.
7[7]Heart protection study collaborative group.MRC/BHF heart protection study of cholesterol lowering with simvastation in 20536 high risk individuals a randomized placebo-controlled trial[J].Lanced,2002,360(9326):7-22.
8[8]Casserly IP,Ziada K,kapadia S,et al.Impait of nonmeasuable borders and variation in cross-section counts on intravascular ultrasound measurement of atherosderofic plaque voleme[J].Am J Cardiol,2002,(9):169-173.
9Albert MA,Danielson E,Rifai N,et al. Effect of statln therapy on C reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE) :a randomized trial and cohort study. JAMA, 2001,286 ( 1 ) :64-70.
10Muhlestein JB, Anderson jL, Home BD. Early effects of statins in patients with coronary artery disease and C-reactive protein. Am J Cardid,2004,94(9) :1107-1112.
